ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
29 announcements with these filters
Quick Heal Technologies Limited shareholders approved the re-appointment of Mr. Richard Stiennon as a Non-Executive Independent Director for a second five-year term, effective September 27, 2026.
Quick Heal Technologies held its 31st Annual General Meeting on September 23, 2026, to conduct business, including the adoption of financial statements and director appointments.
Quick Heal Technologies' Chief Marketing Officer, Sudhanshu Tripathi, has resigned from the company effective September 16, 2026, to pursue other professional opportunities.
Quick Heal Technologies responded to NSE's volume-spurt query, stating all Reg 30 disclosures were made. The company attributes the increase to normal market forces with no undisclosed material event.
Quick Heal Technologies Limited has allotted 9,746 equity shares following the exercise of options under its ESOP Scheme 2021. The exercise prices ranged from ₹114 to ₹122.
Quick Heal Technologies Ltd has appointed Mr. Amit Chaudhary as Vice President – Product Management. This appointment is effective from September 01, 2026.
Quick Heal Technologies Limited has shared the link to its Integrated Annual Report for FY 2025-26 and reminded shareholders to update their KYC details.
Quick Heal Technologies filed its Integrated Annual Report for FY 2025-26. The company also announced its 31st AGM scheduled for September 23, 2026.
Quick Heal Technologies Limited has scheduled its 31st Annual General Meeting for September 23, 2026. The meeting will be conducted via video conferencing with remote e-voting available.
Quick Heal Technologies Limited has approved the grant of 1,02,000 employee stock options under its ESOP Scheme 2021. These options are exercisable at ₹76 per share.
Dr. Lalit Mohan Sanagavarapu has resigned as Chief Product Officer of Quick Heal Technologies Limited, effective August 7, 2026.
Quick Heal Technologies proposed re-appointing Mr. Richard Stiennon as a Non-Executive Independent Director for a second five-year term, pending shareholder approval.
Quick Heal Technologies Ltd reported revenue from operations of ₹45 Cr (-21.3% YoY) and a net loss of ₹5.3 Cr for Q1 FY27.
Quick Heal Technologies allotted 5,332 equity shares upon the exercise of ESOPs. The allotment occurred on July 27, 2026.
Quick Heal Technologies scheduled a Board Meeting for July 30, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.
Quick Heal Technologies allotted 10,286 equity shares under the ESOP Scheme 2021. The allotment followed the exercise of employee stock options.
Quick Heal Technologies allotted 500 equity shares following ESOP exercises. The issuance slightly increases paid-up capital to ₹54.25 Crore, reflecting ongoing employee benefit scheme execution.
Product data sheet for Quick Heal Antivirus Pro highlighting AI-driven security features, GoDeep.AI malware hunting technology, and the SIA virtual assistant.
Quick Heal Technologies Limited filed its Annual Secretarial Compliance Report for FY2025-26. The auditor reported full compliance with SEBI regulations with no fines or observations noted.
Quick Heal is undergoing a painful structural pivot from consumer antivirus to enterprise cybersecurity, resulting in stagnant revenue and its worst-ever quarterly profitability with a ₹11 crore net loss.
Quick Heal Technologies appointed Mr. Rohit Kachroo as Senior Director for IT and Digital Transformation. He brings over 18 years of strategic experience to the role.
Quick Heal Technologies Ltd reported revenue from operations of ₹48.7 Cr (-25.2% YoY) and a net loss of ₹19.9 Cr for Q4 FY26.
Quick Heal reported FY26 consolidated revenue of ₹261.02 Crore and net loss of ₹10.93 Crore. The company appointed Rohit Kachroo as Senior Management Personnel.
Quick Heal clarified that recent share price volatility is driven purely by market forces. The company confirmed all material disclosures have been duly made to exchanges.
Quick Heal Technologies Limited announced the retirement of its Chief Technology Officer, Mr. Ashish Pradhan, effective April 30, 2026. The departure is categorized as cessation due to superannuation.
Mr. Ashish Pradhan has retired as the Chief Technology Officer of Quick Heal Technologies Limited effective April 30, 2026, due to superannuation. This transition marks the departure of a senior management personnel from the company.
Quick Heal Technologies Limited announced the retirement of Mr. Ashish Pradhan from the position of Chief Technology Officer, effective April 30, 2026. Mr. Pradhan had previously received an extension beyond his original retirement date of August 06, 2024. The company has submitted necessary disclosures under SEBI Regulation 30.
Quick Heal Technologies Limited allotted 2,261 equity shares following the exercise of options under its ESOP Scheme 2021. The allotment increases the company's total issued share capital to 5,42,47,716 equity shares. The new shares will rank pari-passu with existing equity and be credited to the permanent ISIN upon trading approval.
Quick Heal Technologies Ltd reported net profit of ₹6.6 Cr (+6500.0% YoY) for Q3 FY26.